Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma

Launched by MAYO CLINIC · Aug 26, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging test called the 68Ga-FAPI-46 PET/CT scan to see if it can help doctors find specific cells related to pancreatic cancer, known as cancer-associated fibroblasts (CAFs). The trial is focused on patients with localized pancreatic ductal adenocarcinoma, which means the cancer has not spread to other parts of the body and can potentially be surgically removed. The goal is to see if this new imaging method can improve the way doctors diagnose and manage this type of cancer.

To participate in the trial, you need to be an adult over 18 years old who has been diagnosed with pancreatic ductal adenocarcinoma but has not yet started treatment. You should also be in good enough health to undergo surgery after receiving some initial therapy. If you are pregnant, breastfeeding, or have certain allergies or other health issues, you may not be eligible to join. If you do take part, you can expect to undergo the PET/CT scan, which combines two types of imaging to provide detailed pictures of your body and help locate the cancer more effectively. This could lead to better treatment options and outcomes for those diagnosed with pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults \> 18 years (yrs.) with treatment-naive biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI, or PET)
• • Localized disease expected to undergo surgical resection following neoadjuvant therapy (NAT)
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• • Ability to provide informed consent
• Exclusion Criteria:
• • Hypersensitivity to any excipients in 68Ga-FAPI-46
• • Require emergency surgery
• • Non-PDA histology on biopsy
• • Histopathologically proven metastatic PDA
• • Pregnant or lactating women